Stilbene derivatives that are colchicine site microtubule inhibitors have antileukemic activity and minimal systemic toxicity

American Journal of Hematology

Volumn 83, Issue 5, 2008, Pages 390-397

  Cao, Thai M ^a   Durrant, David ^b   Tripathi, Ashutosh ^c   Liu, Jihua ^a   Tsai, Schickwann ^a   Kellogg, Glen E ^c   Simoni, Daniele ^d   Lee, Ray M ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; COLCHICINE; CYTARABINE; STILBENE 5C; STILBENE DERIVATIVE; TUBULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BINDING SITE; BONE MARROW CELL; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DAMAGE; CELL DEATH; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STEM CELL; TREATMENT RESPONSE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; CELL CYCLE; COCULTURE TECHNIQUES; COLCHICINE; HELA CELLS; HEMATOPOIETIC STEM CELLS; HL-60 CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; MICE, SCID; MICROTUBULES; PROTO-ONCOGENE PROTEINS C-KIT; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN; TUBULIN MODULATORS; U937 CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 42949169386     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21104     Document Type: Article

References (40)

1. Pace-Asciak CR, Hahn S, Diamandis EP, et al. The red wine phenolics transresveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: Implications for protection against coronary heart disease. Clin Chim Acta 1995;235:207-219.
2. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006;444:337-342.
3. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 2006;127:1109-1122.
4. Le Corre L, Chalabi N, Delort L, et al. Resveratrol and breast cancer chemoprevention: Molecular mechanisms. Mol Nutr Food Res 2005;49:462-471.
5. Larrosa M, Tomas-Barberan FA, Espin JC. The grape and wine polyphenol piceatannol is a potent inducer of apoptosis in human SK-Mel-28 melanoma cells. Eur J Nutr 2004;43:275-284.
6. Kimura Y. New anticancer agents: In vitro and in vivo evaluation of the antitumor and antimetastatic actions of various compounds isolated from medicinal plants. In Vivo 2005;19:37-60.
7. Fulda S, Debatin KM. Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signalling. Eur J Cancer 2005;41:786-798.
8. Rodrigue CM, Porteu F, Navarro N, et al. The cancer chemopreventive agent resveratrol induces tensin, a cell-matrix adhesion protein with signaling and antitumor activities. Oncogene 2005;24:3274-3284.
9. Azios NG, Dharmawardhane SF. Resveratrol and estradiol exert disparate effects on cell migration, cell surface actin structures, and focal adhesion assembly in MDA-MB-231 human breast cancer cells. Neoplasia 2005;7:128-140.
10. Gosslau A, Chen M, Ho CT, et al. A methoxy derivative of resveratrol analogue selectively induced activation of the mitochondrial apoptotic pathway in transformed fibroblasts. Br J Cancer 2005;92:513-521.
11. Belleri M, Ribatti D, Nicoli S, et al. Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4′-trimethoxystilbene. Mol Pharmacol 2005;67:1451-1459.
12. Roberti M, Pizzirani D, Simoni D, et al. Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents. J Med Chem 2003;46:3546-3554.
13. Pettit GR, Singh SB, Hamel E, et al. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989;45: 209-211.
14. Islam MN, Iskander MN. Microtubulin binding sites as target for developing anticancer agents. Mini Rev Med Chem 2004;4:1077-1104.
15. Pellegrini F, Budman DR. Review: Tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest 2005;23:264-273.
16. Gigant B, Wang C, Ravelli RB, et al. Structural basis for the regulation of tubulin by vinblastine. Nature 2005;435:519-522.
17. Ravelli RB, Gigant B, Curmi PA, et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004;428:198-202.
18. Nguyen TL, McGrath C, Hermone AR, et al. A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. J Med Chem 2005;48:6107-6116.
19. Stevenson JP, Rosen M, Sun W, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: Magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003;21:4428-4438.
20. Cooney MM, Radivoyevitch T, Dowlati A, et al. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 2004;10:96-100.
21. Rustin GJ, Galbraith SM, Anderson H, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: Clinical and pharmacokinetic results. J Clin Oncol 2003;21:2815-2822.
22. Beerepoot LV, Radema SA, Witteveen EO, et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 2006;24:1491-1498.
23. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62:3408-3416.
24. Nabha SM, Wall NR, Mohammad RM, et al. Effects of combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines. Anticancer Drugs 2000;11:385-392.
25. Nabha SM, Mohammad RM, Dandashi MH, et al. Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage. Clin Cancer Res 2002;8:2735-2741.
26. Garrido SM, Appelbaum FR, Willman CL, et al. Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol 2001;29:448-457.
27. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003;17:1175-1182.
28. Cao TM, Lo B, Ranheim EA, Grumet FC, et al. Variable hematopoietic graft rejection and graft-versus-host disease in MHC-matched strains of mice. Proc Natl Acad Sci USA 2003;100:11571-11576.
29. Tozer GM, Prise VE, Wilson J, et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues. Cancer Res 1999;59:1626-1634.
30. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415-427.
31. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005;5:423-435.
32. Maxwell RJ, Wilson J, Prise VE, et al. Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed 2002;15:89-98.
33. Galbraith SM, Maxwell RJ, Lodge MA, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21:2831-2842.
34. Anderson HL, Yap JT, Miller MP, et al. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 2003;21:2823-2830.
35. Grosios K, Loadman PM, Swaine DJ, et al. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 2000;20:229-233.
36. Siemann DW, Mercer E, Lepler S, et al. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 2002; 99:1-6.
37. Liu J, Dai Q, Chen J, et al. Phospholipid scramblase 3 controls mitochondrial structure, function, and apoptotic response. Mol Cancer Res 2003;1:892-902.
38. Liu J, Chen J, Dai Q, et al. Phospholipid scramblase 3 is the mitochondrial target of protein kinase c δ-induced apoptosis. Cancer Res 2003;63:1153-1156.
39. Karimi M, Cao TM, Baker JA, et al. Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells. J Immunol 2005;175:7819-7828.
40. Jones G, Willett P, Glen RC, et al. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997;267:727-748.